These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35237910)

  • 1. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
    Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
    Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
    Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
    Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
    Pan M; Li Z; Jia M; Lu X
    Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
    Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
    Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
    Claimon A; Pusuwan P; Khiewvan B
    J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study.
    Wang Y; Wu J; Jiang L; Zhang X; Liu B
    Endocrine; 2022 Apr; 76(1):109-115. PubMed ID: 35094313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer.
    Bandeira L; Padovani RDP; Ticly AL; Cury AN; Scalissi NM; Marone MMS; Ferraz C
    Arch Endocrinol Metab; 2017 Dec; 61(6):590-599. PubMed ID: 29412384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.
    Albano D; Dondi F; Zilioli V; Panarotto MB; Galani A; Cappelli C; Bertagna F; Giubbini R; Casella C
    Ann Nucl Med; 2021 Oct; 35(10):1089-1099. PubMed ID: 34152569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer.
    Szczepanek-Parulska E; Wojewoda-Korbelak M; Borowczyk M; Kaluzna M; Brominska B; Ziemnicka K; Czepczynski R; Baczyk M; Ruchala M
    Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):115-123. PubMed ID: 30221905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
    Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
    Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
    Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
    Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of postoperative stimulated thyroglobulin in differentiated thyroid cancer.
    Elmaraghi C; Shaaban M; Reda C
    Ann Endocrinol (Paris); 2023 Feb; 84(1):32-36. PubMed ID: 36334802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients.
    Garcia Alves-Junior PA; de Andrade Barreto MC; de Andrade FA; Bulzico DA; Corbo R; Vaisman F
    Endocrine; 2024 Jun; 84(3):1081-1087. PubMed ID: 38296913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.